ERBB2 and breast carcinoma: Our study provides fundamental clinical evidence supporting distinct resistance mechanisms in HET and non-HET tumors from both cell-autonomous and non-cell-autonomous sources, potentially paving the way to new, personalized therapeutic opportunities and ultimately bringing us closer to the effective treatment of all patients with HER2-positive breast cancer.